Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Melanoma 31Neoplasms 17Multiple Myeloma 9Thyroid Neoplasms 8Hematologic Neoplasms 7Thyroid Carcinoma, Anaplastic 6Carcinoma, Non-Small-Cell Lung 6Brain Neoplasms 6Lymphoma 5Glioma 5Colorectal Neoplasms 5Thyroid Cancer, Papillary 3Prostatic Neoplasms 3Pancreatic Neoplasms 3Neurofibromatosis 1 3Leukemia, Myeloid, Acute 3Biliary Tract Neoplasms 3Astrocytoma 3Adenocarcinoma, Follicular 3Uveal Melanoma 2Uterine Cervical Neoplasms 2Skin Neoplasms 2Neurofibroma, Plexiform 2Neoplasm Metastasis 2Glioblastoma 2Gastrointestinal Stromal Tumors 2Colonic Neoplasms 2Cholangiocarcinoma 2Carcinoma, Hepatocellular 2Breast Neoplasms 2

Interventions

trametinib 1dabrafenib 1Vincristine 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Ganglioneuroma × trametinib × Clear all
NCT02684058 2023-12-13

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors

Novartis

Phase 2 Completed
151 enrolled 45 charts 1 FDA
CNS

Astrocytoma, Ganglioneuroma, Glioblastoma, Glioma, Oligodendroglioma, Ganglioglioma, Neurocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡